$17.92-0.05 (-0.28%)
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Amneal Pharmaceuticals, Inc. in the Healthcare sector is trading at $17.92 with a market capitalization of $5.2B. Wall Street consensus targets $18.75 (4 analysts), implying a +4.6% move over the next 12 months. The stock is currently near its 52-week high of $18.39, remaining 35.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $722.52M↓ | $814.32M↑ | $784.51M↑ | $724.51M↑ | $695.42M |
| Gross Profit | $320.11M↑ | $297.19M↑ | $273.97M↓ | $286.25M↑ | $255.89M |
| Operating Income | $148.27M↑ | $114.50M↑ | $70.49M↓ | $112.01M↑ | $100.92M |
| Net Income | $62.26M↑ | $35.08M↑ | $2.37M↓ | $22.42M↑ | $12.20M |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internation...
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The company has also beaten the index over the past six months as its stock price is up 26.6%.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The US Food and Drug Administration said Thursday it is requesting updates to prescribing informatio